Skip to content

Study · Non-randomized trial · 1998

4 results

Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).

Mizutani T, Sugihara A, Nakamuro K, Terada N

The Journal of clinical endocrinology and metabolism1 Apr 1998Cited by 36 (Europe PMC)

PMID9543151 (opens in a new tab)DOI10.1210/jcem.83.4.4696 (opens in a new tab)PepBankPUB-09543151
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialMechanism

    In women with leiomyomas, Ki-67-positive cell numbers after leuprolide were comparable with untreated controls at week 2.

    In plain wordsIn women with fibroids, dividing-cell counts after leuprolide were comparable with untreated controls at week 2.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedKi-67-positive cells at week 2
    Study

    n: not reported in source

    Comparator
    Patients without GnRHa therapy
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · injectionAs given in this study (human).

    Source sentences

    Summary
    The number of Ki-67 immunostained cells/cm2 in leiomyomas at the 2nd week of the GnRHa therapy was comparable with that of control patients.
    1 context sentence
    Summary · context
    Patients with uterine leiomyomas were injected with 3.75 mg GnRHa (depot leuprolide acetate) at intervals of 4 weeks and underwent hysterectomy or myomectomy at the 2nd, 4th, 8th, 12th, or 16th week of GnRHa therapy.
  2. 02HumanNon-randomized trialMechanism

    In women with leiomyomas, Ki-67-positive cells fell below one fourth of untreated controls at week 4 and remained low through week 16.

    In plain wordsIn women with fibroids, dividing-cell counts after leuprolide were lower than untreated controls from week 4 through week 16.

    Peptide
    Leuprolide
    Outcome
    DecreaseKi-67-positive cells at weeks 4 to 16
    Study

    n: not reported in source

    Comparator
    Patients without GnRHa therapy
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · injectionAs given in this study (human).

    Source sentences

    Summary
    However, it decreased to a level less than one forth that of control patients at the 4th week, and it remained at similar low levels at the 8th, 12th, and 16th week.
    2 context sentences
    Summary · context
    The number of Ki-67 immunostained cells/cm2 in leiomyomas at the 2nd week of the GnRHa therapy was comparable with that of control patients.
    Summary · context
    Patients with uterine leiomyomas were injected with 3.75 mg GnRHa (depot leuprolide acetate) at intervals of 4 weeks and underwent hysterectomy or myomectomy at the 2nd, 4th, 8th, 12th, or 16th week of GnRHa therapy.
  3. 03HumanNon-randomized trialMechanism

    In women with leiomyomas, DNA end-labeled cells after leuprolide were about 5 times higher than untreated controls at week 4.

    In plain wordsIn women with fibroids, dying-cell counts after leuprolide were about 5 times higher than untreated controls at week 4.

    Peptide
    Leuprolide
    Outcome
    IncreaseApoptosis at week 4
    Study

    n: not reported in source

    Comparator
    Patients without GnRHa therapy
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · injectionAs given in this study (human).

    Measurements

    DNA 3'-end-labeled cells/cm2 relative to control
    ≈ 5 times control level
    week 4 of GnRHa therapy versus control patients

    Source sentences

    Summary
    The number of DNA 3'-end-labeled cells/cm2 in leiomyomas of control patients and in leiomyomas at the 2nd, 8th, 12th, and 16th weeks of GnRHa therapy were at low levels but, at the 4th week, was at an extremely high level (about 5 times more than that of control patients).
    1 context sentence
    Summary · context
    Patients with uterine leiomyomas were injected with 3.75 mg GnRHa (depot leuprolide acetate) at intervals of 4 weeks and underwent hysterectomy or myomectomy at the 2nd, 4th, 8th, 12th, or 16th week of GnRHa therapy.
  4. 04HumanNon-randomized trialMechanism

    In women with leiomyomas, DNA end-labeled cell numbers remained low with leuprolide at weeks 2, 8, 12, and 16, as in controls.

    In plain wordsIn women with fibroids, dying-cell counts remained low after leuprolide at the other assessed weeks, as in untreated controls.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedApoptosis at other assessed weeks
    Study

    n: not reported in source

    Comparator
    Patients without GnRHa therapy
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · injectionAs given in this study (human).

    Source sentences

    Summary
    The number of DNA 3'-end-labeled cells/cm2 in leiomyomas of control patients and in leiomyomas at the 2nd, 8th, 12th, and 16th weeks of GnRHa therapy were at low levels but, at the 4th week, was at an extremely high level (about 5 times more than that of control patients).
    1 context sentence
    Summary · context
    Patients with uterine leiomyomas were injected with 3.75 mg GnRHa (depot leuprolide acetate) at intervals of 4 weeks and underwent hysterectomy or myomectomy at the 2nd, 4th, 8th, 12th, or 16th week of GnRHa therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.